You're welcome. I'm just sharing some info based on what we've...

First 38 Last

Share
Profile

Follow
saltland

432 Posts.

784

09/01/24

23:00

Post #: 71801552
Share

Originally posted by WST: ↑

Very well done and detailed response on RECELL GO issue. I also thought that JC addressed the issue very extensively. The February revenue update should be very interesting. This is the type of innovation that will feed upon it itself with repeat business and market share gains. The company needs to expand research coverage in the U.S., The share volume here is very anemic and given such an exciting innovation, I could see that changing rapidly under the right circumstances.

Expand

Thanks for the feedback. I agree with your comments and think the company is well placed to capitalise on its technology. I'm looking forward to the call in February when hopefully we'll see those circumstances start to change.

Originally posted by Roy2U: ↑

"There are no guarantees when it comes to the FDA"

I agree with your statement @saltland, and thank you so much for your excellent post.

As an investor, I always think about the "what ifs". What if the FDA don't approve Recell Go at the next iteration, but ask further questions or require further tests? The only impact IMO is that the ongoing growth will be at a lower rate than it would have been with an approved Recell Go. But keep in mind that the growth rate now without Recell Go is around 50% and increasing. If anything, some potential buyers might be holding off for Recell Go, so the growth rate could have been higher if Recell Go was never brought into development.

Avita still has a huge competitive advantage by greatly minimising the size of any skin graft donor site. The benefits of this far outweigh the costs of using the existing ease-of-use device, including some training requirements. Reduced hospital stay times and better patient outcomes will ensure Avita continues to grow rapidly and achieve profitability some time during 2025 (on a quarterly basis). Indeed, the growth path for the existing device (in the absence of Recell Go) is enormous, given the indications now approved and the outlook for international expansion.

My investment is not dependent on approval of Recell Go. If it is approved during 2024, the future will be that much better again than my current investment case.

Expand

You're welcome. I'm just sharing some info based on what we've been told in the hope that it helps others with their research, but it's nice to know that it's appreciated so thanks.

Another well written post @Roy2U. I had the same thought process and came to the same conclusion

AVH Price at posting: $4.05 Sentiment: Buy Disclosure: Held
5 Upvote

1 Great analysis

Reply